JP2015503625A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015503625A5 JP2015503625A5 JP2014552357A JP2014552357A JP2015503625A5 JP 2015503625 A5 JP2015503625 A5 JP 2015503625A5 JP 2014552357 A JP2014552357 A JP 2014552357A JP 2014552357 A JP2014552357 A JP 2014552357A JP 2015503625 A5 JP2015503625 A5 JP 2015503625A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- alkynyl
- alkenyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 102
- 125000000217 alkyl group Chemical group 0.000 claims description 101
- 239000001257 hydrogen Substances 0.000 claims description 98
- -1 C (O) NR 2 Chemical group 0.000 claims description 86
- 229910052736 halogen Inorganic materials 0.000 claims description 56
- 150000002367 halogens Chemical class 0.000 claims description 56
- 150000002431 hydrogen Chemical class 0.000 claims description 53
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 45
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 44
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 42
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 40
- 150000001875 compounds Chemical class 0.000 claims description 39
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 39
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 37
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 30
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims description 29
- 229910052717 sulfur Inorganic materials 0.000 claims description 29
- 125000000304 alkynyl group Chemical group 0.000 claims description 28
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 claims description 27
- 229910052760 oxygen Inorganic materials 0.000 claims description 27
- 125000000623 heterocyclic group Chemical group 0.000 claims description 26
- 125000003342 alkenyl group Chemical group 0.000 claims description 24
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 24
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims description 24
- 125000004442 acylamino group Chemical group 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 125000005842 heteroatom Chemical group 0.000 claims description 13
- 229920006395 saturated elastomer Polymers 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 125000002837 carbocyclic group Chemical group 0.000 claims description 11
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 10
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 150000003573 thiols Chemical class 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 16
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 11
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 26
- 125000003545 alkoxy group Chemical group 0.000 description 24
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 0 *C(*)=CC(N(*)c1cccc(*c2c(c(*)c(*)[n]3*)c3nc(N(*)C(C=C)=CC=C(*)N3CCN(*)CC3)n2)c1)=O Chemical compound *C(*)=CC(N(*)c1cccc(*c2c(c(*)c(*)[n]3*)c3nc(N(*)C(C=C)=CC=C(*)N3CCN(*)CC3)n2)c1)=O 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261586718P | 2012-01-13 | 2012-01-13 | |
| US61/586,718 | 2012-01-13 | ||
| PCT/US2013/021338 WO2013106792A1 (en) | 2012-01-13 | 2013-01-12 | Heterocyclic compounds and uses as anticancer agents. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015503625A JP2015503625A (ja) | 2015-02-02 |
| JP2015503625A5 true JP2015503625A5 (cg-RX-API-DMAC10.html) | 2016-03-31 |
| JP6353788B2 JP6353788B2 (ja) | 2018-07-04 |
Family
ID=47604241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014552357A Active JP6353788B2 (ja) | 2012-01-13 | 2013-01-12 | 抗がん剤としての複素環式化合物およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10799504B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2802568A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6353788B2 (cg-RX-API-DMAC10.html) |
| CN (2) | CN104203924B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2013207712B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2861010A1 (cg-RX-API-DMAC10.html) |
| HK (1) | HK1203927A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2013106792A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9464089B2 (en) * | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
| CA2861010A1 (en) | 2012-01-13 | 2013-07-18 | Xiao Xu | Heterocyclic compounds and uses as anticancer agents |
| US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
| US9586965B2 (en) | 2012-01-13 | 2017-03-07 | Acea Biosciences Inc. | Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases |
| CN112592334B (zh) * | 2013-07-11 | 2023-10-27 | 艾森医药公司 | 嘧啶衍生物作为激酶抑制剂 |
| SG11201601138PA (en) | 2013-08-23 | 2016-03-30 | Neupharma Inc | Certain chemical entities, compositions, and methods |
| CN104418858B (zh) * | 2013-08-30 | 2018-12-11 | 浙江医药股份有限公司新昌制药厂 | 2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用 |
| UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
| NO2718543T3 (cg-RX-API-DMAC10.html) * | 2014-02-04 | 2018-01-06 | ||
| NZ629796A (en) * | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| WO2016029002A2 (en) * | 2014-08-22 | 2016-02-25 | Clovis Oncology, Inc. | Growth factor receptor inhibitors |
| CN113121450A (zh) | 2014-08-29 | 2021-07-16 | Tes制药有限责任公司 | α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂 |
| AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| CN107613769A (zh) * | 2015-02-17 | 2018-01-19 | 润新生物公司 | 某些化学实体、组合物和方法 |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| US10533011B2 (en) | 2015-10-09 | 2020-01-14 | ACEA Therapeutics, Inc. | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same |
| CN108473473A (zh) * | 2016-05-06 | 2018-08-31 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白酪氨酸激酶活性的稠合嘧啶类化合物 |
| CA3033370A1 (en) | 2016-08-15 | 2018-02-22 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| WO2018184206A1 (en) | 2017-04-07 | 2018-10-11 | ACEA Therapeutics, Inc. | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same |
| US11440904B2 (en) * | 2017-08-28 | 2022-09-13 | Zhihong Chen | Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof |
| JP7590185B2 (ja) | 2018-06-25 | 2024-11-26 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用 |
| CA3109085A1 (en) * | 2018-08-09 | 2020-02-13 | ACEA Therapeutics, Inc. | Process for manufacture of (s)-n-(3-((2-((4-((1-acetylpyrrolidin-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidin-4-yl)oxy) phenyl)acrylamide, and formulations thereof |
| EP3613738A1 (en) * | 2018-08-23 | 2020-02-26 | Lead Discovery Center GmbH | 4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer |
| US12415816B2 (en) | 2018-11-07 | 2025-09-16 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| WO2020097400A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof |
| US12522583B2 (en) | 2018-11-07 | 2026-01-13 | Dana-Farber Cancer Institute, Inc. | Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof |
| AU2019413694B2 (en) | 2018-12-28 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| EP4146639A1 (en) | 2020-05-06 | 2023-03-15 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| TW202241889A (zh) | 2020-12-23 | 2022-11-01 | 美商雅捷可斯治療公司 | 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| TW202325289A (zh) | 2021-11-09 | 2023-07-01 | 美商雅捷可斯治療公司 | Ｊａｋ２抑制劑之形式及組合物 |
| WO2023086319A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| WO2024092047A1 (en) * | 2022-10-26 | 2024-05-02 | Sorrento Therapeutics, Inc. | Administration of pyrrolopyrimidine-based kinase inhibitors for treatment of psoriasis |
| WO2025155780A1 (en) * | 2024-01-17 | 2025-07-24 | Ohio State Innovation Foundation | Ttk kinase inhibitors and methods of use |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3974277A (en) * | 1974-09-06 | 1976-08-10 | Diamond Shamrock Corporation | 2-[2-(5-Nitro-2-furyl)vinyl]-4-(anilino)quinazolines as growth promotants and feed efficiency enhancing agents |
| US5563905A (en) | 1992-09-24 | 1996-10-08 | Hughes Aircraft Company | Network communication system having time-sliced protocol |
| AU1071301A (en) | 1999-11-01 | 2001-05-14 | Eli Lilly And Company | Pharmaceutical compounds |
| KR100861486B1 (ko) | 2001-02-21 | 2008-10-02 | 미쓰비시 타나베 파마 코퍼레이션 | 퀴나졸린 유도체 |
| US6881737B2 (en) | 2001-04-11 | 2005-04-19 | Amgen Inc. | Substituted triazinyl acrylamide derivatives and methods of use |
| WO2003026666A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors |
| US7560269B2 (en) | 2002-12-20 | 2009-07-14 | Acea Biosciences, Inc. | Real time electronic cell sensing system and applications for cytotoxicity profiling and compound assays |
| US7732127B2 (en) | 2002-12-20 | 2010-06-08 | Acea Biosciences, Inc. | Dynamic monitoring of cell adhesion and spreading using the RT-CES system |
| US7468255B2 (en) | 2002-12-20 | 2008-12-23 | Acea Biosciences | Method for assaying for natural killer, cytotoxic T-lymphocyte and neutrophil-mediated killing of target cells using real-time microelectronic cell sensing technology |
| US7470533B2 (en) | 2002-12-20 | 2008-12-30 | Acea Biosciences | Impedance based devices and methods for use in assays |
| JP2005537498A (ja) | 2002-07-20 | 2005-12-08 | アセア バイオサイエンシーズ，インク． | インピーダンスによる測定装置および方法 |
| WO2004021979A2 (en) | 2002-09-06 | 2004-03-18 | Smithkline Beecham Corporation | PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS |
| WO2004045624A1 (ja) | 2002-11-15 | 2004-06-03 | Mitsubishi Pharma Corporation | 医薬製剤組成物 |
| EP1692258A4 (en) | 2003-11-12 | 2007-03-21 | Xiao Xu | REAL-TIME ELECTRONIC CELL DETECTION SYSTEMS FOR CELL-BASED TESTS |
| SI1696920T1 (sl) | 2003-12-19 | 2015-02-27 | Plexxikon Inc. | Spojine in postopki za razvoj modulatorjev ret |
| US20080207613A1 (en) | 2004-01-12 | 2008-08-28 | Cytopia Research Pty Ltd | Selective Kinase Inhibitors |
| AU2005218655A1 (en) | 2004-03-02 | 2005-09-15 | Neurogen Corporation | Aryl substituted purine analogues |
| AU2005265017A1 (en) | 2004-06-17 | 2006-01-26 | Plexxikon, Inc. | Azaindoles modulating c-kit activity and uses therefor |
| AU2005270068B2 (en) | 2004-07-02 | 2012-04-19 | Exelixis, Inc. | C-Met modulators and method of use |
| HRP20120399T1 (hr) | 2005-09-21 | 2012-06-30 | 4Sc Ag | Novi sulfonilpiroli kao inhibitori hdac |
| EA200800664A1 (ru) | 2005-10-13 | 2009-02-27 | Глаксо Груп Лимитед | Производные пирролопиримидина в качестве ингибиторов syk |
| KR100832593B1 (ko) | 2005-11-08 | 2008-05-27 | 한미약품 주식회사 | 신호전달 저해제로서의 퀴나졸린 유도체 및 이의 제조방법 |
| GB0526246D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| WO2007103233A2 (en) | 2006-03-03 | 2007-09-13 | Aveo Pharmaceuticals, Inc. | Processes for synthesizing 7-alkynyl-4-aminoquinazolines and a related intermediate |
| EA200870385A1 (ru) | 2006-03-29 | 2009-04-28 | Фолдркс Фармасьютикалз, Инк. | Ингибирование токсичности альфа-синуклеина |
| WO2008039359A2 (en) * | 2006-09-25 | 2008-04-03 | Janssen Pharmaceutica N.V. | Bicyclic pyrimidine kinase inhibitors |
| KR101149295B1 (ko) | 2006-12-08 | 2012-07-05 | 아이알엠 엘엘씨 | 단백질 키나제 억제제로서의 화합물 |
| EA200900983A1 (ru) | 2007-01-26 | 2010-02-26 | Айрм Ллк | Соединения и композиции в качестве ингибиторов киназы |
| JP5539734B2 (ja) | 2007-01-31 | 2014-07-02 | ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド | チオピリミジンベースの化合物およびその使用 |
| TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| US7981903B2 (en) | 2007-08-08 | 2011-07-19 | Glaxosmithkline Llc | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer |
| WO2009032703A1 (en) | 2007-08-28 | 2009-03-12 | Irm Llc | 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors |
| TWI475996B (zh) | 2007-10-19 | 2015-03-11 | Celgene Avilomics Res Inc | 雜芳基化合物及其用途 |
| US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| WO2009131687A2 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| PT2300013T (pt) | 2008-05-21 | 2017-10-31 | Ariad Pharma Inc | Derivados de fósforo como inibidores de cinases |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| BRPI0914682B8 (pt) | 2008-06-27 | 2021-05-25 | Avila Therapeutics Inc | compostos de heteroarila e composições compreendendo os referidos compostos |
| WO2010045451A1 (en) | 2008-10-16 | 2010-04-22 | Glaxosmithkline Llc | Pyrrolopyrimidine compounds |
| CA2748943A1 (en) | 2009-02-09 | 2010-08-12 | Supergen, Inc. | Pyrrolopyrimidinyl axl kinase inhibitors |
| US9908884B2 (en) | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
| WO2011079231A1 (en) | 2009-12-23 | 2011-06-30 | Gatekeeper Pharmaceutical, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| US20130137709A1 (en) | 2010-05-05 | 2013-05-30 | Nathanael S. Gray | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith |
| MX342164B (es) | 2010-06-23 | 2016-09-19 | Hanmi Science Co Ltd | Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa. |
| CN103269704B (zh) | 2010-11-01 | 2018-07-06 | 西建卡尔有限责任公司 | 杂环化合物和其用途 |
| US9238629B2 (en) | 2010-11-01 | 2016-01-19 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| EP2637502B1 (en) | 2010-11-10 | 2018-01-10 | Celgene CAR LLC | Mutant-selective egfr inhibitors and uses thereof |
| CN102583089B (zh) | 2011-01-11 | 2015-11-25 | 山东新北洋信息技术股份有限公司 | 薄片类介质处理装置 |
| JP2014513925A (ja) | 2011-03-07 | 2014-06-19 | フォンダッツィオーネ・テレソン | Ｔｆｅｂ変異体およびその使用 |
| JP6147727B2 (ja) | 2011-04-01 | 2017-06-14 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | チロシン受容体キナーゼｂｔｋ阻害剤としての置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体 |
| AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| US8828391B2 (en) | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| US9586965B2 (en) | 2012-01-13 | 2017-03-07 | Acea Biosciences Inc. | Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases |
| CA2861010A1 (en) | 2012-01-13 | 2013-07-18 | Xiao Xu | Heterocyclic compounds and uses as anticancer agents |
| US9464089B2 (en) | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
| US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
| MX361992B (es) | 2012-08-06 | 2018-12-19 | Acea Biosciences Inc | Compuestos de pirrolopirimidina novedosos como inhibidores de proteínas quinasas. |
| CN112592334B (zh) | 2013-07-11 | 2023-10-27 | 艾森医药公司 | 嘧啶衍生物作为激酶抑制剂 |
| CN104306348B (zh) | 2014-09-30 | 2017-05-31 | 地奥集团成都药业股份有限公司 | 一种辛伐他汀片及其制备方法 |
| US10533011B2 (en) | 2015-10-09 | 2020-01-14 | ACEA Therapeutics, Inc. | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same |
| WO2018184206A1 (en) | 2017-04-07 | 2018-10-11 | ACEA Therapeutics, Inc. | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same |
-
2013
- 2013-01-12 CA CA2861010A patent/CA2861010A1/en not_active Abandoned
- 2013-01-12 US US13/740,182 patent/US10799504B2/en active Active
- 2013-01-12 CN CN201380013279.0A patent/CN104203924B/zh not_active Expired - Fee Related
- 2013-01-12 CN CN201910414017.4A patent/CN110194748A/zh active Pending
- 2013-01-12 EP EP13701326.4A patent/EP2802568A1/en not_active Withdrawn
- 2013-01-12 AU AU2013207712A patent/AU2013207712B2/en not_active Ceased
- 2013-01-12 WO PCT/US2013/021338 patent/WO2013106792A1/en not_active Ceased
- 2013-01-12 JP JP2014552357A patent/JP6353788B2/ja active Active
- 2013-01-12 HK HK15104284.0A patent/HK1203927A1/xx unknown
-
2017
- 2017-02-17 US US15/435,722 patent/US10596174B2/en active Active
-
2020
- 2020-08-24 US US17/001,147 patent/US11612602B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015503625A5 (cg-RX-API-DMAC10.html) | ||
| JP2017537080A5 (cg-RX-API-DMAC10.html) | ||
| CY1123616T1 (el) | 7-βενζυλ-4-(4-(τριφθορομεθυλ)βενζυλ)-1,2,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(4η)-ονη, και αλατα αυτης και χρηση αυτων στη θεραπεια | |
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
| RU2015143542A (ru) | Ингибиторы jak2 и alk2 и способы их использования | |
| MY194405A (en) | Dihydropyrimidine compounds and uses thereof in medicine | |
| JP2013510123A5 (cg-RX-API-DMAC10.html) | ||
| JP2018519245A5 (cg-RX-API-DMAC10.html) | ||
| JP2018516238A5 (cg-RX-API-DMAC10.html) | ||
| JP2008535902A5 (cg-RX-API-DMAC10.html) | ||
| JP2014518544A5 (cg-RX-API-DMAC10.html) | ||
| JP2015537020A5 (cg-RX-API-DMAC10.html) | ||
| JP2016503799A5 (cg-RX-API-DMAC10.html) | ||
| MX2013010770A (es) | Tratamiento de tumores solidos. | |
| JP2018529739A5 (cg-RX-API-DMAC10.html) | ||
| JP2017538677A5 (cg-RX-API-DMAC10.html) | ||
| JP2017509689A5 (cg-RX-API-DMAC10.html) | ||
| JP2012508252A5 (cg-RX-API-DMAC10.html) | ||
| RU2016134751A (ru) | Соединения | |
| MX394658B (es) | Compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) y el uso de los mismos | |
| RU2017104856A (ru) | Функционализированные и замещенные индолы в качестве противораковых средств | |
| RU2018114077A (ru) | Биарильное производное и содержащее его лекарственное средство | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| JP2016537382A5 (cg-RX-API-DMAC10.html) |